Baxter International Inc vs Rocket Lab USA Inc — how do they compare? Baxter International Inc trades at $22.31 (market cap $11.26B), while Rocket Lab USA Inc trades at $78.76 (market cap $49.24B). The key difference: Rocket Lab USA Inc is far larger — about 4.4× Baxter International Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| BAX | RKLB | |
|---|---|---|
Market Cap | $11.26B | $49.24B |
Sector | Health | Technology |
52-Week High | $29.22 | $150.23 |
52-Week Low | $15.80 | $39.48 |
Enterprise Value | $18.93B | $48.00B |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Rocket Lab (RKLB) trades at $76.73, down 5.32% over 24 hours, testing key support near $75 amid a bearish technical trend. The company reported Q1 2026 EPS of -$0.02, beating expectations, while revenue reached $601.80M in 2025 with a net loss of -$198.21M. Analyst sentiment remains bullish with a $119.10 consensus price target, supported by recent strategic moves like the Iridium acquisition announced July 13, 2026.
The outlook hinges on execution of growth initiatives and path to profitability, with risks including high cash burn and competitive pressures. Upside potential exists if operational efficiencies improve and satellite revenue scales, but investors face volatility from negative margins and sector headwinds.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →